Chugai Notches Up Record Earnings in January-September on Hemlibra, Mainstays

October 25, 2019
Chugai Pharmaceutical delivered record sales and profits in the first nine month of 2019, buoyed by its hemophilia drug Hemlibra’s (emicizumab) bullish market penetration and steady revenues from new and mainstay portfolios. In January-September, the Roche group company recorded sales...read more